Lebwohl M - Search Results

1

Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis.

Blauvelt A, Gooderham M, Griffiths CEM, Armstrong AW, Zhu B, Burge R, Gallo G, Guo J, Garrelts A, Lebwohl M. Blauvelt A, et al. Among authors: lebwohl m. Dermatol Ther (Heidelb). 2022 Mar;12(3):727-740. doi: 10.1007/s13555-022-00690-5. Epub 2022 Feb 23. Dermatol Ther (Heidelb). 2022. PMID: 35195887 Free PMC article.

2

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE; Alefacept Clinical Study Group. Lebwohl M, et al. Arch Dermatol. 2003 Jun;139(6):719-27. doi: 10.1001/archderm.139.6.719. Arch Dermatol. 2003. PMID: 12810502 Clinical Trial.

3

The use of alefacept in the treatment of psoriasis.

Wong VK, Lebwohl M. Wong VK, et al. Among authors: lebwohl m. Skin Therapy Lett. 2003 Sep;8(6):1-2, 7. Skin Therapy Lett. 2003. PMID: 14610613 Free article. Review.

4

An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis.

Gribetz CH, Blum R, Brady C, Cohen S, Lebwohl M. Gribetz CH, et al. Among authors: lebwohl m. J Am Acad Dermatol. 2005 Jul;53(1):73-5. doi: 10.1016/j.jaad.2005.03.053. J Am Acad Dermatol. 2005. PMID: 15965424 Clinical Trial.

5

Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate.

van de Kerkhof P, Griffiths CE, Christophers E, Lebwohl M, Krueger GG. van de Kerkhof P, et al. Among authors: lebwohl m. Dermatology. 2005;211(3):256-63. doi: 10.1159/000087020. Dermatology. 2005. PMID: 16205071 Clinical Trial.

6

Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies.

Lebwohl M, Menter A, Weiss J, Clark SD, Flores J, Powers J, Balin AK, Kempers S, Glinert RJ, Fleming T, Liu Y, Graeber M, Pariser DM. Lebwohl M, et al. J Drugs Dermatol. 2007 Apr;6(4):428-35. J Drugs Dermatol. 2007. PMID: 17668541 Clinical Trial.

7

Combining systemic retinoids with biologic agents for moderate to severe psoriasis.

Smith EC, Riddle C, Menter MA, Lebwohl M. Smith EC, et al. Among authors: lebwohl m. Int J Dermatol. 2008 May;47(5):514-8. doi: 10.1111/j.1365-4632.2008.03470.x. Int J Dermatol. 2008. PMID: 18412874

8

New biologics for psoriasis and psoriatic arthritis.

Rozenblit M, Lebwohl M. Rozenblit M, et al. Among authors: lebwohl m. Dermatol Ther. 2009 Jan-Feb;22(1):56-60. doi: 10.1111/j.1529-8019.2008.01216.x. Dermatol Ther. 2009. PMID: 19222517 Review.

9

Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation.

Menon K, Van Voorhees AS, Bebo BF Jr, Gladman DD, Hsu S, Kalb RE, Lebwohl MG, Strober BE; National Psoriasis Foundation. Menon K, et al. J Am Acad Dermatol. 2010 Feb;62(2):291-9. doi: 10.1016/j.jaad.2009.03.047. Epub 2009 Jul 31. J Am Acad Dermatol. 2010. PMID: 19646777 Review.

10

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.

Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG. Lebwohl M, et al. Br J Dermatol. 2010 Jan;162(1):137-46. doi: 10.1111/j.1365-2133.2009.09491.x. Epub 2009 Nov 9. Br J Dermatol. 2010. PMID: 19903183 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

753 results

Search Page

Filters